{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T12:32:46Z","timestamp":1763641966950},"reference-count":18,"publisher":"Impact Journals, LLC","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncotarget"],"published-print":{"date-parts":[[2014,6,30]]},"DOI":"10.18632\/oncotarget.1937","type":"journal-article","created":{"date-parts":[[2015,9,15]],"date-time":"2015-09-15T23:39:30Z","timestamp":1442360370000},"page":"4170-4179","source":"Crossref","is-referenced-by-count":18,"title":["The poison oligonucleotide F10 is highly effective against acute lymphoblastic leukemia while sparing normal hematopoietic cells"],"prefix":"10.18632","volume":"5","author":[{"given":"Timothy S.","family":"Pardee","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Section on Hematology and Oncology, Wake Forest University School of Medicine, Winston-Salem, NC"},{"name":"Comprehensive Cancer Center of Wake Forest University, Winston-Salem, NC"},{"name":"Department of Cancer Biology, Comprehensive Cancer Center of Wake Forest University, Winston-Salem, NC"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristin","family":"Stadelman","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Section on Hematology and Oncology, Wake Forest University School of Medicine, Winston-Salem, NC"},{"name":"Comprehensive Cancer Center of Wake Forest University, Winston-Salem, NC"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jamie","family":"Jennings-Gee","sequence":"additional","affiliation":[{"name":"Department of Cancer Biology, Comprehensive Cancer Center of Wake Forest University, Winston-Salem, NC"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David L.","family":"Caudell","sequence":"additional","affiliation":[{"name":"Department of Pathology, Section of Comparative Medicine, Wake Forest University School of Medicine, Winston-Salem, NC"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William H.","family":"Gmeiner","sequence":"additional","affiliation":[{"name":"Department of Cancer Biology, Comprehensive Cancer Center of Wake Forest University, Winston-Salem, NC"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"7892","published-online":{"date-parts":[[2014,5,1]]},"reference":[{"issue":"9881","key":"1","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.1016\/S0140-6736(12)62187-4","article-title":"Acute lymphoblastic leukaemia","volume":"381","author":"Mullighan","year":"2013","journal-title":"Lancet"},{"issue":"6","key":"2","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1182\/blood-2012-05-378943","article-title":"Pediatric acute lymphoblastic leukemia: where are we going and how do we get there?","volume":"120","author":"Relling","year":"2012","journal-title":"Blood"},{"issue":"7","key":"3","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1182\/blood-2008-06-164863","article-title":"Improvement in survival in younger patients with acute lymphoblastic leukemia from the 1980s to the early 21st century","volume":"113","author":"Gondos","year":"2009","journal-title":"Blood"},{"key":"4","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1182\/asheducation-2010.1.13","article-title":"Treating the \u201colder\u201d adult with acute lymphoblastic leukemia","volume":"2010","author":"Marks","year":"2010","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"5","first-page":"79","article-title":"Treatment of older patients with acute lymphoblastic leukemia","volume":"85","author":"Larson","year":"2006","journal-title":"Annals of Hematology"},{"issue":"3","key":"6","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1182\/blood-2006-05-018192","article-title":"Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12\/ECOG 2993 study","volume":"109","author":"Goldstone","year":"2007","journal-title":"Blood"},{"issue":"23","key":"7","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1056\/NEJMoa062867","article-title":"Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia","volume":"355","author":"Reiffers","year":"2006","journal-title":"N Engl J Med"},{"issue":"25","key":"8","doi-asserted-by":"crossref","first-page":"6521","DOI":"10.1182\/blood-2011-05-351403","article-title":"Dasatinib as first-line treatment for adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia","volume":"118","author":"Zuffa","year":"2011","journal-title":"Blood"},{"issue":"5","key":"9","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1182\/blood.V88.5.1788.1788","article-title":"Oligonucleotide uptake in human hematopoietic cells is increased in leukemia and is related to cellular activation","volume":"88","author":"Krieg","year":"1996","journal-title":"Blood"},{"issue":"15","key":"10","doi-asserted-by":"crossref","first-page":"3561","DOI":"10.1182\/blood-2011-06-362442","article-title":"Unique dual targeting of thymidylate synthase and topoisomerase1 by FdUMP[10] results in high efficacy against AML and low toxicity","volume":"119","author":"Gmeiner","year":"2012","journal-title":"Blood"},{"issue":"13","key":"11","doi-asserted-by":"crossref","first-page":"3585","DOI":"10.1182\/blood-2010-08-301267","article-title":"Chemotherapeutic agents circumvent emergence of dasatinib-resistant BCR-ABL kinase mutations in a precise mouse model of Philadelphia chromosome-positive acute lymphoblastic leukemia","volume":"117","author":"Williams","year":"2011","journal-title":"Blood"},{"issue":"2","key":"12","first-page":"e184","article-title":"Replication-dependent irreversible topoisomerase 1 poisoning is responsible for FdUMP[10] anti-leukemic activity","volume":"41","author":"Gmeiner","year":"2013","journal-title":"Exp Hematol"},{"issue":"23","key":"13","doi-asserted-by":"crossref","first-page":"3185","DOI":"10.1200\/JCO.2011.34.8144","article-title":"Mutations and deletions of the TP53 gene predict nonresponse to treatment and poor outcome in first relapse of childhood acute lymphoblastic leukemia","volume":"29","author":"Kirschner-Schwabe","year":"2011","journal-title":"J Clin Oncol"},{"issue":"3","key":"14","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1038\/nm.3078","article-title":"Activating mutations in the NT5C2 nucleotidase gene drive chemotherapy resistance in relapsed ALL","volume":"19","author":"Rabadan","year":"2013","journal-title":"Nat Med"},{"issue":"31","key":"15","doi-asserted-by":"crossref","first-page":"5208","DOI":"10.1200\/JCO.2009.22.5748","article-title":"5-year survival in patients with relapsed or refractory chronic lymphocytic leukemia in a randomized, phase III trial of fludarabine plus cyclophosphamide with or without oblimersen","volume":"27","author":"Rai","year":"2009","journal-title":"J Clin Oncol"},{"issue":"7","key":"16","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/j.leukres.2005.10.025","article-title":"A Phase II study of Bcl-2 antisense (oblimersen sodium) combined with gemtuzumab ozogamicin in older patients with acute myeloid leukemia in first relapse","volume":"30","author":"Marcucci","year":"2006","journal-title":"Leuk Res"},{"issue":"15","key":"17","doi-asserted-by":"crossref","first-page":"3404","DOI":"10.1200\/JCO.2005.09.118","article-title":"Phase I study of oblimersen sodium, an antisense to Bcl-2, in untreated older patients with acute myeloid leukemia: pharmacokinetics, pharmacodynamics, and clinical activity","volume":"23","author":"Larson","year":"2005","journal-title":"J Clin Oncol"},{"key":"18","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/1471-2342-8-16","article-title":"Tumor volume in subcutaneous mouse xenografts measured by microCT is more accurate and reproducible than determined by 18F-FDG-microPET or external caliper","volume":"8","author":"Kjaer","year":"2008","journal-title":"BMC Med Imaging"}],"container-title":["Oncotarget"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.1937","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,13]],"date-time":"2020-05-13T19:35:11Z","timestamp":1589398511000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.1937"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,5,1]]},"references-count":18,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2014,6,30]]}},"alternative-id":["1937","24961587"],"URL":"https:\/\/doi.org\/10.18632\/oncotarget.1937","relation":{},"ISSN":["1949-2553"],"issn-type":[{"value":"1949-2553","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,5,1]]}}}